<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TRIMETHOBENZAMIDE HYDROCHLORIDE - trimethobenzamide hydrochloride capsule </strong><br>REMEDYREPACK INC. <br></p></div>
<h1>TRIMETHOBENZAMIDE HYDROCHLORIDE CAPSULES USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1>SPL UNCLASSIFIED</h1>
<p class="First"></p>
<p><span class="Bold">Rx only</span></p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"></p>
<p>Chemically, trimethobenzamide HCl is N-[<span class="Italics">p</span>-[2-(dimethylamino)ethoxy]benzyl]-3,4,5-trimethoxybenzamide monohydrochloride. It has a molecular weight of 424.93 and the following structural formula:</p>
<p><img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=760afbcd-bc81-4595-82c8-ec1cbd7c2b08&amp;name=MM1.jpg"></p>
<p>Each capsule for oral use contains trimethobenzamide hydrochloride equivalent to 300 mg.</p>
<p>Inactive Ingredients: FDA/E172 Red Iron Oxide, gelatin, magnesium stearate, microcrystalline cellulose, sodium starch glycolate and titanium dioxide. The imprinting ink contains D&amp;C Yellow #10 Lake, FD&amp;C Blue #1, FD&amp;C Blue #2, FD&amp;C Red #40, Iron Oxide Black, propylene glycol and shellac glaze.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<p>The mechanism of action of trimethobenzamide hydrochloride capsules, USP as determined in animals is obscure, but may involve the chemoreceptor trigger zone (CTZ), an area in the medulla oblongata through which emetic impulses are conveyed to the <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> center; direct impulses to the <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> center apparently are not similarly inhibited. In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> induced by intragastric copper sulfate.</p>
<p>
 
</p>
<p></p>
<p>The pharmacokinetics of trimethobenzamide have been studied in healthy adult subjects. Following administration of 200 mg (100 mg/mL) trimethobenzamide hydrochloride I.M. injection, the time to reach maximum plasma concentration (T<span class="Sub">max</span>) was about half an hour, about 15 minutes longer for trimethobenzamide hydrochloride 300 mg oral capsule than an I.M. injection. A single dose of trimethobenzamide hydrochloride 300 mg oral capsule provided a plasma concentration profile of trimethobenzamide similar to trimethobenzamide hydrochloride 200 mg I.M. The relative bioavailability of the capsule formulation compared to the solution is 100%. The mean elimination half-life of trimethobenzamide is 7 to 9 hours. Between 30 – 50% of a single dose in humans is excreted unchanged in the urine within 48–72 hours. The major pathway of trimethobenzamide metabolism is through oxidation resulting in the formation of trimethobenzamide N-oxide metabolite. The pharmacologic activity of this major metabolite has not been evaluated.</p>
<p>
 
</p>
<p></p>
<p>
 
</p>
<p></p>
<p>The clearance of trimethobenzamide is not known in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. However, it may be advisable to consider reduction in the dosing of trimethobenzamide in elderly patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> considering that a substantial amount of excretion and elimination of trimethobenzamide occurs via the kidney and that elderly patients may have various degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (See <span class="Bold"><a href="#genprec">PRECAUTIONS: General</a></span> and <span class="Bold"><a href="#dosadmin">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>
 
</p>
<p></p>
<p>Systemic exposure to trimethobenzamide was similar between men (N=40) and women (N=28).</p>
<p>
 
</p>
<p></p>
<p>Pharmacokinetics appeared to be similar for Caucasians (N=53) and African Americans (N=12).</p>
<p>
 
</p>
<p></p>
<p>The clearance of trimethobenzamide is not known in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. However, it may be advisable to consider reduction in the dosing of trimethobenzamide in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> considering that a substantial amount of excretion and elimination of trimethobenzamide occurs via the kidney. (See <span class="Bold"><a href="#genprec">PRECAUTIONS: General</a></span> and <span class="Bold"><a href="#dosadmin">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<p class="First"></p>
<p>Trimethobenzamide hydrochloride capsules, USP are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and for <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> associated with <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"></p>
<p>Use of any dosage form in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to trimethobenzamide is contraindicated.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"></p>
<p>Caution should be exercised when administering trimethobenzamide hydrochloride capsules, USP to children for the treatment of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Antiemetics are not recommended for treatment of uncomplicated <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> in children and their use should be limited to prolonged <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> of known etiology. There are two principal reasons for caution:</p>
<ol>
<li>The <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> which can occur secondary to trimethobenzamide      hydrochloride capsules, USP may be <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confused</span> with the central nervous system signs of an undiagnosed primary disease responsible for the <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, e.g., Reye's syndrome or other <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>.</li>
<li> It has been suspected that drugs with hepatotoxic potential, such as trimethobenzamide hydrochloride capsules, USP, may unfavorably alter the course of Reye's syndrome. Such drugs should therefore be avoided in children whose signs and symptoms (<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>) could represent Reye's syndrome.</li>
</ol>
<p>Trimethobenzamide hydrochloride capsules, USP may produce <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>. Patients should not operate motor vehicles or other dangerous machinery until their individual responses have been determined.</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Usage in Pregnancy: </span>  Trimethobenzamide hydrochloride was studied in reproduction experiments in rats and rabbits and no <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was suggested. The only effects observed were an increased percentage of embryonic resorptions or stillborn pups in rats administered 20 mg and 100 mg/kg and increased resorptions in rabbits receiving 100 mg/kg. In each study these adverse effects were attributed to one or two dams. The relevance to humans is not known. Since there is no adequate experience in pregnant or lactating women who have received this drug, safety in pregnancy or in nursing mothers has not been established.</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Usage with Alcohol: </span> Concomitant use of alcohol with trimethobenzamide hydrochloride capsules, USP may result in an adverse drug interaction.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"></p>
<p>During the course of acute febrile illness, encephalitides, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, especially in children and the elderly or debilitated, CNS reactions such as <span class="product-label-link" type="condition" conceptid="4313849" conceptname="Opisthotonus">opisthotonos</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> have been reported with and without use of trimethobenzamide hydrochloride capsules, USP or other antiemetic agents. In such disorders caution should be exercised in administering trimethobenzamide hydrochloride capsules, USP, particularly to patients who have recently received other CNS-acting agents (phenothiazines, barbiturates, belladonna derivatives). Primary emphasis should be directed toward the restoration of body fluids and electrolyte balance, the relief of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and relief of the causative disease process. <span class="product-label-link" type="condition" conceptid="4266976" conceptname="Overhydration">Overhydration</span> should be avoided since it may result in <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span>.</p>
<p>The antiemetic effects of trimethobenzamide hydrochloride capsules, USP may render diagnosis more difficult in such conditions as <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">appendicitis</span> and obscure signs of toxicity due to overdosage of other drugs.</p>
<p>
 
</p>
<p></p>
<p>Adjustment of Dose in <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span></p>
<p>A substantial route of elimination of unchanged trimethobenzamide is via the kidney. Dosage adjustment should be considered in patients with reduced renal function including some elderly patients. (See <span class="Bold"><a href="#clinical">CLINICAL PHARMACOLOGY</a></span> and <span class="Bold"><a href="#dosadmin">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>
 
</p>
<p></p>
<p>Clinical studies of trimethobenzamide hydrochloride did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Although there are studies reported in the literature that included elderly patients &gt;65 years old with younger patients, it is not known if there are differences in efficacy or safety parameters for elderly and non-elderly patients treated with trimethobenzamide. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See <span class="Bold"><a href="#clinical">CLINICAL PHARMACOLOGY</a></span> and <span class="Bold"><a href="#dosadmin">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"></p>
<p>There have been reports of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> and Parkinson-like symptoms. There have been instances of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> reported following parenteral administration to surgical patients. There have been reports of <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurring of vision</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of mood, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span> and <span class="product-label-link" type="condition" conceptid="4313849" conceptname="Opisthotonus">opisthotonos</span>. If these occur, the administration of the drug should be discontinued. Allergic-type <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> have been observed; therefore, the drug should be discontinued at the first sign of sensitization. While these symptoms will usually disappear spontaneously, symptomatic treatment may be indicated in some cases.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<p class="First"></p>
<p>(See <span class="Bold"><a href="#warnings">WARNINGS</a></span> and <span class="Bold"><a href="#precautions">PRECAUTIONS</a></span>.)</p>
<p>Dosage should be adjusted according to the indication for therapy, severity of symptoms and the response of the patient.</p>
<p>
 
</p>
<p></p>
<p>Dose adjustment such as reducing the total dose administered at each dosing or increasing the dosing interval should be considered in elderly patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance ≤70 mL/min/1.73m<span class="Sup">2</span>). Final dose adjustment should be based upon integration of clinical efficacy and safety considerations. (See <span class="Bold"><a href="#clinical">CLINICAL PHARMACOLOGY</a></span> and <span class="Bold"><a href="#precautions">PRECAUTIONS</a></span>).</p>
<p>
 
</p>
<p></p>
<p>In subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance ≤70 mL/min/1.73m<span class="Sup">2</span>), dose adjustment such as reducing the total dose administered at each dosing or increasing the dosing interval should be considered. (See <span class="Bold"><a href="#clinical">CLINICAL PHARMACOLOGY</a></span> and <span class="Bold"><a href="#precautions">PRECAUTIONS</a></span>).</p>
<p>CAPSULES, 300 mg</p>
<p><span class="Italics">Usual Adult Dosage</span></p>
<p>One 300 mg capsule t.i.d. or q.i.d.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"></p>
<p>Trimethobenzamide hydrochloride capsules, USP are supplied as follows:</p>
<p>Trimethobenzamide hydrochloride capsules, USP 300 mg, swedish orange opaque, imprinted MUTUAL over 401 on both the body and cap.</p>
<table width="50%">
<col align="left" span="1" valign="top" width="50%">
<col align="left" span="1" valign="top" width="50%">
<tbody class="Headless">
<tr class="First">
<td align="left">Bottles of 30</td>
<td align="left">NDC 53489-376-07</td>
</tr>
<tr>
<td align="left">Bottles of 60</td>
<td align="left">NDC 53489-376-06</td>
</tr>
<tr>
<td align="left">Bottles of 100</td>
<td align="left">NDC 53489-376-01</td>
</tr>
<tr>
<td align="left">Bottles of 250</td>
<td align="left"> NDC 53489-376-03</td>
</tr>
<tr>
<td align="left">Bottles of 500</td>
<td align="left">NDC 53489-376-05</td>
</tr>
<tr class="Last">
<td align="left">Bottles of 1000 </td>
<td align="left"> NDC 53489-376-10</td>
</tr>
</tbody>
</table>
<p>
 
</p>
<p></p>
<p>Store at 20° to 25°C (68° to 77°F).</p>
<p>[See USP Controlled Room Temperature]</p>
<p>DISPENSE IN TIGHT, LIGHT-RESISTANT CONTAINER.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<h1>SPL UNCLASSIFIED</h1>
<p class="First"></p>
<p>Manufactured by:<br>Mutual Pharmaceutical Company, Inc.<br>Philadelphia, PA 19124  USA</p>
<p>Rev 04, November 2010</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
<p class="First">
    DRUG: Trimethobenzamide Hydrochloride </p>
<p><br></p>
<p>GENERIC: Trimethobenzamide Hydrochloride</p>
<p><br></p>
<p>DOSAGE: CAPSULE</p>
<p><br></p>
<p>ADMINSTRATION: ORAL</p>
<p><br></p>
<p>NDC: 49349-496-17</p>
<p><br></p>
<p>ACTIVE INGREDIENT(S):</p>
<ul><li>Trimethobenzamide Hydrochloride 300mg in 1</li></ul>
<p><br></p>
<p>INACTIVE INGREDIENT(S):</p>
<ul>
<li>Aluminum oxide</li>
<li>FD&amp;C blue no. 2</li>
<li>FD&amp;C red no. 40</li>
<li>FD&amp;C blue no. 1</li>
<li>ferrosoferric oxide</li>
<li>propylene glycol</li>
<li>shellac</li>
<li>Sodium Starch Glycolate Type A Potato</li>
<li>gelatin</li>
<li>magnesium stearate</li>
<li>cellulose, microcrystalline</li>
<li>D&amp;C yellow no. 10</li>
<li>ferric oxide red</li>
<li>titanium dioxide</li>
</ul>
<p><br></p>
<p>COLOR: brown</p>
<p><br></p>
<p>SHAPE: CAPSULE</p>
<p><br></p>
<p>SCORE: No score</p>
<p><br></p>
<p>SIZE: 18 mm</p>
<p><br></p>
<p>IMPRINT: MUTUAL;401</p>
<p><br></p>
<p>PACKAGING: 4  in 1 BOTTLE</p>
<p><br></p>
<p><br></p>
<p><br></p>
<p><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=760afbcd-bc81-4595-82c8-ec1cbd7c2b08&amp;name=MM2.jpg"></p>
<p><img alt="MM3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=760afbcd-bc81-4595-82c8-ec1cbd7c2b08&amp;name=MM3.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TRIMETHOBENZAMIDE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">trimethobenzamide hydrochloride capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49349-496(NDC:53489-376)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Trimethobenzamide Hydrochloride</strong> (TRIMETHOBENZAMIDE) </td>
<td class="formItem">Trimethobenzamide Hydrochloride</td>
<td class="formItem">300 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Aluminum oxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C blue no. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C red no. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C blue no. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferrosoferric oxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>shellac</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Starch Glycolate Type A Potato</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C yellow no. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">brown</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (CAPSULE) </td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MUTUAL;401</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49349-496-17</td>
<td class="formItem">4  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076570</td>
<td class="formItem">12/31/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>REMEDYREPACK INC. 
							(829572556)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 12/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ed700ef1-a802-4673-ae82-f7c8bedd6921</div>
<div>Set id: 760afbcd-bc81-4595-82c8-ec1cbd7c2b08</div>
<div>Version: 1</div>
<div>Effective Time: 20131231</div>
</div>
</div> <div class="DistributorName">REMEDYREPACK INC. </div></p>
</body></html>
